An Operational Roadmap for Drug Repurposing of Registered Pharmaceuticals: A Four-Stage Model Bypassing Early Clinical Phases
This paper presents a replicable four-stage operational roadmap for drug repurposing that enables mid-sized manufacturers to bypass early clinical phases by strategically sequencing scientific validation, early intellectual property protection, Phase IV trials, and regulatory dossier construction to significantly reduce development costs and timelines.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
The journey of creating a new medicine is famously difficult and expensive. It often takes more than a decade and costs over a billion dollars to bring a single new drug to the market, with most attempts failing along the way. This high barrier means that many smaller pharmaceutical companies cannot afford to invent new medicines from scratch, leaving a vast amount of therapeutic potential locked inside drugs that are already approved and sitting on pharmacy shelves. These existing medicines have known safety records and manufacturing processes, yet their ability to treat different conditions often goes unnoticed. The concept of drug repurposing offers a way to unlock this potential by taking a drug that is already registered for one use and proving it works for a new one. Instead of starting from zero, scientists can skip the earliest, most expensive years of testing because the drug's safety in humans is already documented. However, until now, there has been no clear, step-by-step guide for companies to follow this path, particularly regarding how to protect their new ideas legally before they share their findings with the world.
A team of researchers from Brazil has now mapped out a practical, four-stage roadmap to solve this problem, turning the theory of repurposing into a working strategy. Their work is based on a real-world project where they took a long-standing Brazilian medicine, originally designed to support the nervous system with vitamins and amino acids, and successfully tested it for treating motion sickness. The team demonstrated that by following a specific sequence of steps, a company can validate a new use for an old drug in a fraction of the time and cost required for a new invention. The core of their discovery is a method to bypass the early clinical phases entirely. Because the drug was already known to be safe for humans, the researchers were able to jump straight to the final stage of testing, which confirmed that the medicine worked better than existing treatments for seasickness. This approach saved an estimated 65 to 75 percent of the usual development costs and cut the timeline by eight to twelve years.
The researchers organized their successful project into four distinct stages that any company with a registered product could follow. The first stage is building a scientific case. Before spending money on new tests, the team conducted a thorough review of existing literature to find evidence that the ingredients in their drug could logically help with motion sickness. They found that the drug's components interact with the brain and inner ear in ways that could calm the nausea caused by movement. This step acts as a filter, ensuring that a company only moves forward if the science makes sense. The second stage, which the authors identified as critical, is securing legal protection before making any public announcements. In their project, the team filed for a trademark for the new name of the medicine and applied for a patent that covers the specific use of the drug for motion sickness. They learned a valuable lesson here: in their actual project, they filed the patent after they had already published the clinical study, which is a public record. This delay meant they might have lost some legal protection. Their new model corrects this by insisting that all legal filings happen before any public disclosure, ensuring the company keeps its exclusive rights to the new use for as long as possible.
The third stage is the clinical validation, where the team proved the drug actually worked. Instead of running the small, early tests usually required for new drugs, they went straight to a large, randomized study involving 335 volunteers. These participants took the medicine or a standardized ginger extract (the active comparator) before taking several real trips on urban transport to see if they felt sick. The results showed that the group taking the medicine had significantly less motion sickness than the group taking the ginger extract. The study was rigorous, using a standard questionnaire to measure the results, and the drug was found to be safe, with side effects that were mild and consistent with what was already known about the medicine. This single study served the same purpose as the three earlier phases of drug development that are usually required, effectively replacing years of work with one focused trial.
Finally, the fourth stage involves assembling the official application to get the new use approved by health regulators. The team did not have to start a new file from scratch. Instead, they took the existing safety and manufacturing records for the original drug and simply added the new evidence from their study and their scientific review. This process, known as an incremental evaluation, allowed the health authority to focus only on the new information rather than re-checking everything about the drug. The result was a streamlined path to approval that leveraged decades of existing data. The authors found that this entire process, from the initial idea to the submission of the final application, took less than two years. Their work proves that for mid-sized companies, the most efficient way to innovate is not always to invent something new, but to carefully re-examine what they already have, protect the new idea immediately, and use the known safety of the product to fast-track its approval for a new purpose.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.